adefovir dipivoxil + indinavir + lamivudine

Adefovir dipivoxil + indinavir + lamivudine is a hypothetical or research-use combination of three distinct antiretroviral drugs: adefovir dipivoxil (a nucleotide reverse transcriptase inhibitor used primarily against hepatitis B virus and with off-label/experimental use in HIV), indinavir (a protease inhibitor used in combination antiretroviral therapy for HIV), and lamivudine (a nucleoside reverse transcriptase inhibitor used for both HIV and hepatitis B). - There is clinical evidence for the use of **adefovir dipivoxil** in combination with **lamivudine** for chronic hepatitis B, particularly in lamivudine-resistant cases, due to their additive antiviral effects and resistance profiles[1][3][7]. - While both **lamivudine** and **adefovir dipivoxil** have independent and additive antiviral activity against HIV, and **indinavir** is a classic component of HIV HAART regimens, there is minimal documentation for the simultaneous clinical use of all three agents as a fixed or standard combination. - **Mechanisms of action**: - **Adefovir dipivoxil**: Prodrug of adefovir, an acyclic nucleotide analogue; inhibits viral DNA polymerases of HBV, HIV, and some other DNA viruses by competing with dATP and causing chain termination[2][4][6]. - **Lamivudine**: Cytidine analogue (NRTI); inhibits reverse transcriptase of both HBV and HIV by chain termination after incorporation into viral DNA. - **Indinavir**: Inhibits HIV-1 protease, preventing cleavage of viral polyproteins and the formation of mature infectious virions. - **Indication** (by inference): Theoretical or off-label use for HIV (especially as salvage therapy in highly treatment-experienced patients or those with resistance to standard regimens), or for chronic hepatitis B with HIV co-infection, though not a standard or approved fixed combination as of current knowledge.

Other names

adefovir dipivoxil and indinavir and lamivudineadefovir dipivoxil + indinavir sulfate + lamivudine